Read Our Latest Whitepaper
Read Our Latest Whitepaper
Building on Part I in our series, we believe that the adoption of genAI/ agentic AI in precision diagnostics will unlock even more potential for investors. This is based on five 'must have's':
Ready to use, available data for precision Dx
Alignment of AI advancements with regulation around Dx models and data
Harmonized, standardized Dx systems, not tests
Actionable, genAI/ agentic-based dashboards for biopharma, clinician and patient decisioning
Emergence of new, robust precision Dx business models alongside reimbursement
Building on Part I in our series, we believe that the adoption of genAI/ agentic AI in precision diagnostics will unlock even more potential for investors. This is based on five 'must have's':
Ready to use, available data for precision Dx
Alignment of AI advancements with regulation around Dx models and data
Harmonized, standardized Dx systems, not tests
Actionable, genAI/ agentic-based dashboards for biopharma, clinician and patient decisioning
Emergence of new, robust precision Dx business models alongside reimbursement
Our Investment Thesis
Our Investment Thesis
Our Investment Thesis
We focus on pre-seed and seed drug delivery, bio tools and diagnostic companies in the US, UK, Europe, and Israel that have potential to attract venture capital funding and commercial partnerships in the US. We not only provide start-up capital, but also accelerate product-market fit and guide startups through the critical fundraising, partnering and commercialization process in the US market, through our extensive network.
Our approach ensures a clear pathway to scaling, with targeted support in securing follow-on funding and establishing partnerships. We typically exit through partnerships or high-value M&A opportunities—maximizing both investor returns and industry impact.
We focus on pre-seed and seed drug delivery, bio tools and diagnostic companies in the US, UK, Europe, and Israel that have potential to attract venture capital funding and commercial partnerships in the US. We not only provide start-up capital, but also accelerate product-market fit and guide startups through the critical fundraising, partnering and commercialization process in the US market, through our extensive network.
Our approach ensures a clear pathway to scaling, with targeted support in securing follow-on funding and establishing partnerships. We typically exit through partnerships or high-value M&A opportunities—maximizing both investor returns and industry impact.
We focus on pre-seed biopharma platforms, tools and diagnostics companies in the US, UK, Europe, and Israel that have potential to attract venture capital funding and commercial partnerships in the US. We not only provide start-up capital, but also accelerate product-market fit and guide startups through the critical fundraising, partnering and commercialization process in the US market, through our extensive network.
Our approach ensures a clear pathway to scaling, with targeted support in securing follow-on funding and establishing partnerships. We typically exit through partnerships or high-value M&A opportunities–maximizing both investor returns and industry impact.
Portfolio
Our investments span all the way from precision medicine platforms and services to diagnostic tests. Take a look at some of our investments:
Our investments span all the way from precision medicine platforms and services to diagnostic tests.
Why We Invest
Why We Invest
We believe that early stage drug delivery, bio tools and diagnostics are on the cusp of major growth, due to advances in multiomics data and genAI/ agentic AI.
Historically, the sector has been underfunded relative to therapeutics, but recent VC rounds and exist in 2024 and 1H 2025 are showing an uptick in activity, as documented in Pitchbook's Q4 2024 report.
We believe that early stage drug delivery, bio tools and diagnostics are on the cusp of major growth, due to advances in multiomics data and genAI/ agentic AI.
Historically, the sector has been underfunded relative to therapeutics, but recent VC rounds and exist in 2024 and 1H 2025 are showing an uptick in activity, as documented in Pitchbook's Q4 2024 report.
Meet Our Team
Meet Our Team
Get to know the passionate individuals behind our work and discover what drives us.
Get to know the passionate individuals behind our work and discover what drives us.
